Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022067269 - ANTIBODIES AGAINST SARS-COV-2

Publication Number WO/2022/067269
Publication Date 31.03.2022
International Application No. PCT/US2021/052481
International Filing Date 28.09.2021
IPC
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 2039/507
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
507Comprising a combination of two or more separate antibodies
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
Applicants
  • HUMABS BIOMED SA [CH]/[CH]
  • CORTI, Davide [IT]/[CH]
  • DE MARCO, Anna [IT]/[CH]
  • PIZZUTO, Matteo Samuele [IT]/[CH]
  • GUARINO, Barbara [CH]/[CH]
  • LEMPP, Florian [DE]/[US]
  • CHEN, Alex [US]/[US]
  • ROSEN, Laura [US]/[US]
Inventors
  • CORTI, Davide
  • DE MARCO, Anna
  • PIZZUTO, Matteo Samuele
  • GUARINO, Barbara
  • LEMPP, Florian
  • CHEN, Alex
  • ROSEN, Laura
Agents
  • MORGAN, John, A.
  • OBEIDAT, Baha, A.
  • ADRA, Bilal, H.
  • KUMABE, Blake, K.
  • SOLTANI, Bobby, B.
  • ZENTZ, Bradley, J.
  • SARGEANT, Brooke
  • QUIST, Brooke, W.
  • EIDT, Chandra, E.
  • O'BRIEN, Daniel
  • CARLSON, David, V.
  • CONLEE, David C.
  • STARK, Duncan
  • TARLETON, E., Russell
  • SUN, Eileen, S.
  • HARWOOD, Eric, A.
  • HAN, Hai
  • TALBERT, Hayley, J.
  • KHANNA, Hemant
  • PURUSHE, Janaki
  • BARRETT, Jared, M.
  • DANLEY, Jeffrey E.
  • SAKOI, Jeffrey, M.
  • BAUNACH, Jeremiah, J.
  • GRITTON, Jessica, S.
  • ZHANG, Jianping
  • WAKELEY, John, J.
  • COE, Justin, E.
  • HENCKEL, Karen, M.
  • HEFTER, Karl, A.
  • HERMANNS, Karl, R.
  • TOYAMA, Kazuya
  • MORGAN, Kevan, L.
  • COSTANZA, Kevin, S.
  • COOPER, Michael, P.
  • LECOINTE, Michelle, M.
  • BENDEMIRE, Paul, D.
  • LIN, Qing
  • WEBB, Samuel, E.
  • LIU, Shi
  • LEEK, Shoko, I.
  • ROSENMAN, Stephen, J.
  • LAWRENZ, Steven, D.
  • ABEDI, Syed
  • BOLLER, Timothy, L.
  • SHEWMAKE, Thomas, A.
  • LIGON, Toby, J.
  • LI, Yiheng
  • SAKOI, Zachary, M.
Priority Data
63/084,50128.09.2020US
63/111,43509.11.2020US
63/112,50511.11.2020US
63/119,54530.11.2020US
63/137,11213.01.2021US
63/170,35602.04.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ANTIBODIES AGAINST SARS-COV-2
(FR) ANTICORPS CONTRE LE SARS-COV-2
Abstract
(EN) The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. In certain embodiments, an antibody or antigen-binding fragment is capable of binding to a SARS-CoV-2 spike protein in the N-terminal domain (NTD). Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors that comprise a polynucleotide, host cells that express an antibody or antigen-binding fragment, pharmaceutical compositions, and methods for treating or diagnosing a SARS-CoV-2 infection.
(FR) La présente invention concerne des anticorps et des fragments de liaison à l'antigène de ceux-ci qui peuvent se lier à un antigène du SARS-CoV-2 et, dans certains modes de réalisation, peuvent neutraliser une infection par le SARS-CoV-2. Dans certains modes de réalisation, un anticorps ou un fragment de liaison à l'antigène est capable de se lier à une protéine de spicule du SARS-CoV-2 dans le domaine N-terminal (NTD). L'invention concerne également des polynucléotides qui codent pour un anticorps ou un fragment de liaison à l'antigène, des vecteurs qui comprennent un polynucléotide, des cellules hôtes qui expriment un anticorps ou un fragment de liaison à l'antigène, des compositions pharmaceutiques et des méthodes de traitement ou de diagnostic d'une infection par le SARS-CoV-2.
Latest bibliographic data on file with the International Bureau